Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
In Wednesday's pre-market trading, shares of Novo Nordisk A/S (NYSE:NVO) are witnessing a fall after the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk's semaglutide, Wegovy, to reduce the risk of heart complications or strokes in overweight and obese adults,
周三盘前交易中，Novo Nordisk A/S (NYSE:NVO) 的股票价格下跌，此前英国药品与保健品管制局 (MHRA) 批准了 Novo Nordisk 的一种新型治疗药Semaglutide（商标名为Wegovy），旨在减少超重和肥胖成年人心脏并发症或中风的风险。
What Happened: At the time of writing, Novo Nordisk was trading 1.25% lower at $131.61 in the pre-market after closing at $133.28 on Tuesday, according to Benzinga Pro.
事件经过：截至撰写本文时，Novo Nordisk 的股票交易价格为131.61美元，较周二的133.28美元下跌1.25%，据Benzinga Pro报道。
The weak pre-market performance can also be linked to increased competition in the weight loss drugs market. Last week, shares of Novo Nordisk and rival Eli Lilly (NYSE:LLY) dipped after Pfizer Inc. (NYSE:PFE) and Roche (OTC:RHHBY) announced their advancements in obesity-fighting drugs.
对于 Novo Nordisk 股票的弱势盘前表现，也可以归因于减重药市场竞争加剧。上周，Novo Nordisk 和竞争对手 Eli Lilly (NYSE:LLY) 的股票价格都出现下跌，此前辉瑞（Pfizer Inc.，NYSE:PFE）和罗氏（Roche，OTC:RHHBY）宣布其在治疗肥胖方面的药物研发取得了进展。
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management, in combination with diet, physical activity, and behavioral support.
Semaglutide是一种GLP-1受体激动剂，先前已经获得批准用于肥胖治疗和体重管理，可以和饮食、体育锻炼和行为支持相结合使用。
This latest approval marks semaglutide as the first weight loss drug to be prescribed for the prevention of cardiovascular events, such as cardiovascular death, non-fatal heart attack, and non-fatal stroke, in individuals with established cardiovascular disease and a Body Mass Index (BMI) of 27 kg/m2 or higher.
这种最新的药品批准标志着Semaglutide成为可用于预防心血管事件的第一种减肥药物，例如心血管死亡、非致命性心肌梗塞和非致命性中风，适用于已经患有心血管疾病和身体质量指数（BMI）为27 kg/m2或更高的个人。
The approval is based on new data from a post-approval clinical study, which demonstrated that semaglutide (2.4 mg once weekly by subcutaneous injection for up to five years) reduces the occurrence of major adverse cardiovascular events (MACE) compared to a placebo.
该批准基于一项最新的批准后临床研究数据，显示皮下注射1周2.4毫克的Semaglutide（最长为5年）与安慰剂相比，可以减少重大不良心血管事件（MACE）的发生。
Why It Matters: This approval comes after Novo Nordisk acquired Cardior Pharmaceuticals GmbH in April, a biotech company focusing on heart diseases, as the Danish pharma giant sought to build its heart drugs pipeline.
此次批准是在Novo Nordisk于4月份收购了心脏疾病生物技术公司Cardior Pharmaceuticals GmbH之后才获得的，作为丹麦制药巨头增强其心血管药品管道。
In June, Wegovy demonstrated greater weight loss in women with prevalent heart disease than in men with the same condition. The drug led to similar improvements in heart failure symptoms in both genders, but women lost an average of 9.6% of their weight, compared to men who lost about 7.2% of body weight.
今年6月，Wegovy对于患有普遍心脏病的女性而言的减重效果优于男性。该药物对于两性的心力衰竭症状改善类似，但女性平均减重9.6%，而男性只减少了7.2%的体重。
- Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
- Ozempic和Zepbound的减肥效应热潮让糖尿病患者没了重要的GLP-1类药物
Photo by Tobias Arhelger via Shutterstock
图片由shutterstock提供
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本报道使用Benzinga Neuro生成，并由Pooja Rajkumari编辑